

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Asymchem Laboratories (Tianjin) Co., Ltd.

凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

2026 THIRD QUARTERLY REPORT

This announcement is made by Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”) and the Inside Information Provisions (as defined in the Hong Kong Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Asymchem Laboratories (Tianjin) Co., Ltd. 2026 Quarterly Report for the Third Quarter” published by the Company on the website of the Shenzhen Stock Exchange, for reference purposes only. The third quarterly report for 2026 of the Company (the “**2026 Third Quarterly Report**”) is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the report shall prevail.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee of the Company, but have not been reviewed by the independent auditors of the Company.

The unaudited financial data in the 2026 Third Quarterly Report set out in this announcement is prepared in accordance with the Chinese Accounting Standards for Business Enterprises of the People's Republic of China and/or the International Financial Reporting Standards (the “**IFRSs**”) issued by the International Accounting Standards Board (as applicable), and is prepared pursuant to the requirements of the Main Board of the Shenzhen Stock Exchange.

By order of the Board

Asymchem Laboratories (Tianjin) Co., Ltd.

Dr. Hao Hong

Chairperson of the Board, Executive Director and Chief Executive Officer

Tianjin, the PRC, 22 October 2026

As of the date of this announcement, the Board comprises Dr. Hao Hong as the Chairperson of the Board and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Dr. Sun Xuejiao, Dr. Hou Xinyi and Mr. Xie Weikai as independent non-executive Directors.

Asymchem Laboratories (Tianjin) Co., Ltd.

2026 QUARTERLY REPORT FOR THE THIRD QUARTER

The Company and all members of the Board hereby confirm that the information disclosed herein is true, accurate and complete and does not contain any false information, misleading statements or material omissions.

IMPORTANT NOTICE:

1. The Board, the Directors and the senior management of the Company confirm that the quarterly report does not contain any false information, misleading statements or material omissions, and individually and collectively accept responsibility for the truthfulness, accuracy and completeness of its contents.
2. The person in charge of the Company, the chief financial officer and the person in charge of the accounting department (accounting head) of the Company hereby confirm the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
3. Whether this third quarterly report is audited or not
☐ Yes ☒ No

I. MAJOR ACCOUNTING DATA

(I) Major Accounting Data and Financial Indicators

Does the Company require a retroactive adjustment or restatement on the financial data in prior years

☐ Yes ☒ No

	For the three months ended 30 September 2026 (the "Reporting Period")	Increase/decrease for the Reporting Period as compared with the same period of last year	From the beginning of the year to the end of the Reporting Period	Increase/decrease from the beginning of the year to the end of the Reporting Period as compared to the same period of last year
Operating Revenue (RMB)	1,788,094,157.34	24.04%	5,394,933,459.85	16.52%
Net profit attributable to shareholders of the listed company (RMB)	331,722,555.57	81.49%	852,184,750.57	6.49%
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss (RMB)	203,499,460.45	25.70%	728,302,029.06	0.04%
Net cash flow from operating activities (RMB)	N/A	N/A	605,316,294.45	(47.10%)
Basic earnings per share (RMB per share)	0.91	82.00%	2.36	8.26%
Diluted earnings per share (RMB per share)	0.91	82.00%	2.36	8.26%
Weighted average return on net assets	1.85%	0.79%	4.75%	0.12%

	At the end of the Reporting Period	At the end of last year	Increase/decrease as at the end of the Reporting Period as compared to the end of the last year
Total assets (<i>RMB</i>)	21,633,891,908.88	20,277,465,751.10	6.69%
Owners' equity attributable to shareholders of the listed company (<i>RMB</i>)	17,807,191,525.37	17,635,098,689.32	0.98%

(II) Brief Summary of the Operation During the Reporting Period

Currently, the CDMO industry has shown positive momentum. Keeping abreast of the innovative drug industry, the Company continued to step up its efforts in market expansion, capability building and capacity construction, particularly in incremental business segments such as peptides, oligonucleotides and antibody-drug conjugates (ADCs), laying a solid foundation for sustained and steady growth in results. During the Reporting Period, newly signed orders of the Company maintained double-digit year-on-year growth. As late-stage clinical or commercial CDMO projects are characterized by large supply volumes, relatively long execution cycles and strong planning requirements, the corresponding orders are usually delivered in a more concentrated manner in the second half of the year. Based on the Company's orders backlog pending delivery, the delivery scale in the fourth quarter is expected to increase significantly as compared with the Reporting Period. The Company expects its operating revenue for the full year of 2026 to increase by 19% to 22%.

In the first three quarters of 2026, the Company recorded total operating revenue of RMB5,395 million, representing a year-on-year increase of 16.52%, or 20.00% on a constant currency basis. Among which, revenue for the third quarter amounted to RMB1,788 million, representing a year-on-year increase of 24.04%, or 28.25% on a constant currency basis. In the first three quarters of 2026, revenue from the small molecule CDMO business amounted to RMB3,465 million, representing a year-on-year increase of 3.59%, or 7.44% on a constant currency basis; revenue from emerging businesses amounted to RMB1,923 million, representing a year-on-year increase of 50.20%, or 52.69% on a constant currency basis, mainly driven by the strong growth of the chemical macromolecules, biological macromolecules and drug product business segments. The Company accelerated its global market expansion and continued to broaden its customer base. Based on customer type, revenue from large pharmaceutical companies amounted to RMB2,513 million in the first three quarters of 2026, representing a year-on-year increase of 22.40%, while revenue from small and medium-sized pharmaceutical companies amounted to RMB2,882 million, representing a year-on-year increase of 11.84%. Based on region, revenue from customers in overseas markets amounted to RMB3,623 million, demonstrating a year-on-year increase of 11.64% on a constant currency basis, while revenue from customers in the domestic market amounted to RMB1,772 million, reflecting a year-on-year increase of 42.83%.

In 2026, with improving operating efficiency as its core focus, the Company shifted from a “cost reduction and efficiency enhancement” approach to a “cost control and efficiency improvement” approach, to materially enhance business profitability and competitiveness. In the first three quarters of 2026, the Company recorded gross profit of RMB2,259 million, representing a year-on-year increase of 23.17% on a constant currency basis, and an overall gross profit margin of 41.88%, representing an increase of 1.12 percentage points year-on-year on a constant currency basis. Among which, the gross profit margin of the small molecule business was 47.97%, representing an increase of 0.97 percentage points year-on-year, or 49.83% on a constant currency basis, demonstrating an increase of 2.84 percentage points year-on-year. The gross profit margin of the emerging business was 30.95%, reflecting an increase of 0.41 percentage points year-on-year, while on a constant currency basis, the gross profit margin was 32.08%, up 1.53 percentage points year-on-year. In the first three quarters of 2026, profit attributable to shareholders of the listed company amounted to RMB852 million, representing a year-on-year increase of 6.49%. The growth in net profit lagged behind that of revenue, primarily attributable to the impact of exchange rate fluctuations; adjusted net profit attributable to shareholders of the listed company reached RMB1,074 million, reflecting a year-on-year increase of 21.81%.

(III) Non-recurring Profit or Loss Items and Amount

☒ Applicable ☐ Not Applicable

Items	<i>Unit: RMB</i>	
	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period
Gains or losses on disposal of non-current assets (including the written-off portion of provision for asset impairment)	(2,054,352.15)	(7,449,408.40)
Subsidies included in profit or loss for the Reporting Period (excluding those closely relevant to the Company’s normal operations, in compliance with laws and regulations, in accordance with determined standards, and have a continuous impact on the Company’s profit or loss)	19,423,201.43	37,476,425.99
Apart from effective hedging activities relating to the normal operations of the Company, profit or loss from change in fair value of financial assets and financial liabilities held by non-financial enterprises, and gains or losses arising from the disposal of held-for-trading financial assets and held-for-trading financial liabilities	121,284,605.96	104,400,045.11
Other non-operating gain and loss other than the above	14,355,777.68	14,208,240.28
Less: Effect of income tax	24,724,397.03	24,577,887.78
Effect of non-controlling interests (after tax)	61,740.77	174,693.69
Total	<u>128,223,095.12</u>	<u>123,882,721.51</u>

Details of other profit or loss items that meet the definition of non-recurring profits or losses:

☐ Applicable ☒ Not Applicable

The Company has no other profit or loss items that meet the definition of non-recurring profits or losses.

Explanation on the non-recurring profit or loss items listed in the Explanatory Announcement on Information Disclosure by Companies Offering Securities to the Public No. 1 – Non-recurring Profits or Losses as recurring profit or loss items.

☐ Applicable ☒ Not Applicable

The Company does not define the non-recurring profit or loss items listed in the Explanatory Announcement on Information Disclosure by Companies Offering Securities to the Public No. 1 – Non-recurring Profits or Losses as recurring profit or loss items.

(IV) Changes in the Major Accounting Data and Financial Indicators and the Reasons Thereof

☒ Applicable ☐ Not Applicable

Unit: RMB

No.	Items of balance sheet	30 September 2026	1 January 2026	Percentage of change	Reasons for change
1	Monetary funds	4,183,369,564.97	6,320,950,478.94	(33.82%)	Primarily due to the increase in purchases of bank wealth management products and the increase in capital expenditure during the Reporting Period
2	Held-for-trading financial assets	2,461,309,388.50	1,116,583,752.06	120.43%	Primarily due to the increase in outstanding bank wealth management products at the end of the Reporting Period
3	Inventories	2,429,940,576.41	1,470,881,789.26	65.20%	Primarily due to the impact of order delivery cycles
4	Other current assets	293,717,535.71	173,795,711.12	69.00%	Primarily due to the increase in retained VAT credits during the Reporting Period
5	Other non-current assets	675,744,675.64	446,006,831.76	51.51%	Primarily due to the increase in prepayments for equipment and construction works during the Reporting Period
6	Contract liabilities	418,329,256.78	251,469,737.14	66.35%	Primarily due to the increase in advance payments received from customers
7	Other payables	872,178,141.66	562,866,730.64	54.95%	Primarily due to the increase in payables for equipment and construction works and changes in restricted shares during the Reporting Period
8	Long-term borrowings	320,000,000.00	–	100.00%	Primarily due to bank borrowings obtained during the Reporting Period
9	Treasury shares	1,146,781,917.07	838,449,170.33	36.77%	Primarily due to share repurchases during the Reporting Period

No.	Items of income statement	Amount for the period from January to September 2026	Amount for the previous period from January to September 2025	Percentage of change	Reasons for change
1	Finance costs	175,780,850.83	(89,760,104.64)	295.83%	Primarily due to exchange losses arising from exchange rate fluctuations during the Reporting Period
2	Investment income	133,362,461.23	46,171,416.29	188.84%	Primarily due to the increase in gains from associates during the Reporting Period

No.	Items of statement of cash flows	Amount for the period from January to September 2026	Amount for the previous period from January to September 2025	Percentage of change	Reasons for change
1	Receipts of tax refunds	132,285,930.47	255,321,328.87	(48.19%)	Primarily due to the decrease in refunds of retained VAT credits received during the Reporting Period
2	Cash received from returns on investments	197,957,927.78	121,103,847.08	63.46%	Primarily due to the increase in investment dividends and interest on wealth management products received during the Reporting Period
3	Cash received relating to other investing activities	13,747,875,542.20	8,808,496,506.81	56.08%	Primarily due to the increase in redemptions of bank wealth management products during the Reporting Period
4	Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,408,553,554.16	838,008,321.52	68.08%	Primarily due to the increase in construction of new plants and purchases of equipment during the Reporting Period
5	Cash payments relating to other investing activities	12,974,355,829.60	8,205,047,033.02	58.13%	Primarily due to the increase in purchases of bank wealth management products during the Reporting Period
6	Cash received from capital contribution	365,368,231.38	160,334,216.00	127.88%	Primarily due to the receipt of subscription payments under the employee share incentive scheme during the Reporting Period
7	Cash received from borrowings	449,783,598.29	–	100.00%	Primarily due to the increase in bank loans during the Reporting Period
8	Cash payments relating to other financing activities	378,211,280.32	85,962,276.36	339.97%	Primarily due to the repurchase of the Company's shares during the Reporting Period
9	Effect of foreign exchange rate changes on cash and cash equivalents	(194,696,500.77)	1,214,672.47	(16,128.72%)	Primarily due to exchange rate fluctuations during the Reporting Period

II. INFORMATION OF SHAREHOLDERS

(I) Total Number of Ordinary Shareholders and Number of Preferred Shareholders with Restored Voting Rights and Shareholdings of the Top Ten Shareholders

Unit: Share

Total number of ordinary shareholders at the end of the Reporting Period	52,011	Total number of preferred shareholders with restored voting rights at the end of the Reporting Period (if any)	—
--	--------	--	---

Shareholdings of the top ten shareholders (without refinancing's securities lending business)

Name of Shareholder	Nature of Shareholder	Shareholding ratio	Number of shares held	Number of restricted shares held	Pledged, tagged or frozen Share status	Number
ASYMCHEM LABORATORIES, INCORPORATED	Foreign legal person	31.81%	115,133,168	—	Not applicable	—
HKSCC NOMINEES LIMITED ^{Note 1}	Foreign legal person	7.69%	27,833,949	—	Not applicable	—
HAO HONG	Foreign natural person	3.94%	14,268,699	10,701,524	Not applicable	—
Industrial and Commercial Bank of China Limited – China Europe Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 – 中歐醫療健康混合型證券投資基金)	Others	3.68%	13,311,461	—	Not applicable	—
Hong Kong Securities Clearing Co., Ltd. (香港中央結算有限公司)	Foreign legal person	2.81%	10,162,199	—	Not applicable	—
Tianjin Guorong Business Information Consulting Co., Ltd. (天津國榮商務信息諮詢有限公司)	Domestic non-state-owned legal person	1.66%	6,002,004	—	Not applicable	—
Bank of China Limited – Hwabao CSI Medical ETF (中國銀行股份有限公司 – 華寶中證醫療交易型開放式指數證券投資基金)	Others	1.54%	5,562,138	—	Not applicable	—
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Drug Industry ETF (上海銀行股份有限公司 – 銀華中證創新藥產業交易型開放式指數證券投資基金)	Others	0.86%	3,112,182	—	Not applicable	—
Industrial and Commercial Bank of China Limited – China Europe Healthcare Innovation Equity Securities Investment Fund (中國工商銀行股份有限公司 – 中歐醫療創新股票型證券投資基金)	Others	0.85%	3,090,729	—	Not applicable	—
Bank of China Limited – China Merchants Guozheng Biomedicine Index Structured Securities Investment Fund (中國銀行股份有限公司 – 招商國證生物醫藥指數分級證券投資基金)	Others	0.80%	2,902,632	—	Not applicable	—

**Shareholding of top ten shareholders without selling restrictions
(excluding refinancing releasing shares and shares locked up for senior management)**

Name of Shareholder	Number of shares held without selling restrictions	Types and number of shares	
		Types of shares	Number
ASYMCHEM LABORATORIES, INCORPORATED	115,133,168	RMB-denominated ordinary shares	115,133,168
HKSCC NOMINEES LIMITED ^{Note 1}	27,833,949	Overseas listed foreign shares	27,833,949
Industrial and Commercial Bank of China Limited – China Europe Health Hybrid Securities Investment Fund (中國工商銀行股份有限公司 – 中歐醫療健康混合型證券投資基金)	13,311,461	RMB-denominated ordinary shares	13,311,461
Hong Kong Securities Clearing Co., Ltd. (香港中央結算有限公司)	10,162,199	RMB-denominated ordinary shares	10,162,199
Tianjin Guorong Business Information Consulting Co., Ltd. (天津國榮商務信息諮詢有限公司)	6,002,004	RMB-denominated ordinary shares	6,002,004
Bank of China Limited – Hwabao CSI Medical ETF (中國銀行股份有限公司 – 華寶中證醫療交易型開放式指數證券投資基金)	5,562,138	RMB-denominated ordinary shares	5,562,138
HAO HONG	3,567,175	RMB-denominated ordinary shares	3,567,175
Bank of Shanghai Co., Ltd. – Yinhua CSI Innovative Drug Industry ETF (上海銀行股份有限公司 – 銀華中證創新藥產業交易型開放式指數證券投資基金)	3,112,182	RMB-denominated ordinary shares	3,112,182
Industrial and Commercial Bank of China Limited – China Europe Healthcare Innovation Equity Securities Investment Fund (中國工商銀行股份有限公司 – 中歐醫療創新股票型證券投資基金)	3,090,729	RMB-denominated ordinary shares	3,090,729
Bank of China Limited – China Merchants Guozheng Biomedicine Index Structured Securities Investment Fund (中國銀行股份有限公司 – 招商國證生物醫藥指數分級證券投資基金)	2,902,632	RMB-denominated ordinary shares	2,902,632

Illustrations on the connected relationship or acting in concert for the shareholders above

Dr. HAO HONG is the controlling shareholder and de facto controller of ALAB and is related to ALAB. Save for the above connected relationship, the Company is not aware of other shareholders who were connected or acted in concert with each other.

Note 1: HKSCC NOMINEES LIMITED, being “香港中央結算(代理人)有限公司”, holds shares on behalf of various customers, and the Company is unable to confirm whether such shares are pledged, tagged or frozen.

Margin trading and short selling by top ten shareholders (if any)

Tianjin Guorong Business Information Consulting Co., Ltd. held a total of 6,002,004 A shares, of which 5,855,504 shares are held through a credit securities account and 146,500 shares are held through an ordinary account.

Information on the shareholders holding more than 5% of the shares, the top ten shareholders and the top ten shareholders without selling restrictions participating in the refinancing’s securities lending business

☐ Applicable ☒ Not Applicable

Change in the top ten shareholders and the top ten shareholders without selling restrictions from the previous period due to the shares lending or returning of refinancing’s securities lending business

☐ Applicable ☒ Not Applicable

(II) Total Number of Preferred Shareholders and Shareholdings of the Top Ten Preferred Shareholders of the Company

☐ Applicable ☒ Not Applicable

III. OTHER SIGNIFICANT EVENTS

☐ Applicable ☒ Not Applicable

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Financial Statement

1. Consolidated Balance Sheet

Prepared by: Asymchem Laboratories (Tianjin) Co., Ltd.
30 September 2026

Unit: RMB

Item	Amount at the End of the Reporting Period	Amount at the Beginning of the Year
Current Assets:		
Monetary funds	4,183,369,564.97	6,320,950,478.94
Financial assets held for trading	2,461,309,388.50	1,116,583,752.06
Notes receivable	66,216,620.74	31,465,106.30
Accounts receivable	2,081,327,263.75	1,946,020,867.42
Prepayments	128,240,387.29	125,053,878.96
Other receivables	31,957,069.48	24,646,787.13
Inventories	2,429,940,576.41	1,470,881,789.26
Contract assets	95,270,082.01	83,164,964.19
Non-current assets due within one year	31,862,041.60	213,772,216.82
Other current assets	293,717,535.71	173,795,711.12
Total current assets	11,803,210,530.46	11,506,335,552.20

Item	Amount at the End of the Reporting Period	Amount at the Beginning of the Year
Non-current assets:		
Long-term equity investments	626,020,408.99	573,469,427.49
Other non-current financial assets	188,174,403.88	193,522,690.63
Fixed assets	5,116,851,785.17	4,496,051,074.13
Construction in progress	1,938,946,511.02	1,827,245,252.51
Right-of-use assets	253,040,069.58	272,807,780.81
Intangible assets	482,730,081.29	421,799,644.57
Goodwill	146,183,447.05	146,183,447.05
Long-term prepaid expenses	102,833,930.75	118,425,052.19
Deferred tax assets	300,156,065.05	275,618,997.76
Other non-current assets	675,744,675.64	446,006,831.76
Total non-current assets	9,830,681,378.42	8,771,130,198.90
Total assets	21,633,891,908.88	20,277,465,751.10
Current liabilities:		
Short-term borrowings	80,000,000.00	—
Derivative financial liabilities	11,211,343.28	9,836,379.78
Accounts payable	729,437,798.82	589,037,239.77
Contract liabilities	418,329,256.78	251,469,737.14
Employee benefits payable	339,889,406.43	369,394,828.79
Taxes payable	118,098,489.82	133,144,460.94
Other payables	872,178,141.66	562,866,730.64
Current portion of non-current liabilities	55,624,064.49	52,711,245.99
Other current liabilities	205,772.94	26,949.16
Total current liabilities	2,624,974,274.22	1,968,487,572.21

Item	Amount at the End of the Reporting Period	Amount at the Beginning of the Year
Non-current liabilities:		
Long-term borrowings	320,000,000.00	—
Lease liabilities	233,798,952.57	256,473,140.36
Long-term payables	178,215,848.31	—
Provision	27,562.29	27,562.29
Deferred income	326,436,015.70	294,734,010.04
Deferred tax liabilities	139,896,255.28	111,603,640.83
Total non-current liabilities	1,198,374,634.15	662,838,353.52
Total liabilities	3,823,348,908.37	2,631,325,925.73
Owners' equity:		
Share capital	375,454,694.00	360,560,720.00
Capital reserve	9,160,738,004.15	9,066,927,466.12
Less: Treasury shares	1,146,781,917.07	838,449,170.33
Other comprehensive income	7,669,716.31	20,601,270.38
Special reserve	590,709.14	940,713.88
Surplus reserve	208,970,876.28	208,970,876.28
Retained earnings	9,200,549,442.56	8,815,546,812.99
Total equity attributable to owners of the parent company	17,807,191,525.37	17,635,098,689.32
Non-controlling interests	3,351,475.14	11,041,136.05
Total owners' equity	17,810,543,000.51	17,646,139,825.37
Total liabilities and owners' equity	21,633,891,908.88	20,277,465,751.10

Legal representative:
HAO HONG

Accounting chief:
Zhang Da

Person-in-charge of the
accounting department:
Huang Mo

2. Consolidated Statement of Profit from the Beginning of the Year to the End of the Reporting Period

Unit: RMB

Item	Amount for the Period (January- September 2026)	Amount for the Previous period (January- September 2025)
I. Total operating revenue	5,394,933,459.85	4,629,877,130.98
Of which: Operating revenue	5,394,933,459.85	4,629,877,130.98
II. Total operating costs	4,554,994,753.90	3,776,377,340.05
Of which: Operating cost	3,135,572,858.28	2,664,983,604.57
Tax and surcharges	46,710,177.30	35,192,437.51
Selling expenses	172,083,346.36	150,218,668.55
Administrative expenses	669,177,960.88	582,671,328.75
R&D expenses	355,669,560.25	433,071,405.31
Finance costs	175,780,850.83	(89,760,104.64)
Of which: Interest expense	11,025,588.55	9,388,152.19
Interest income	98,925,396.33	152,063,519.49
Add: Other income	55,536,025.90	52,146,160.76
Investment income (loss is represented by “()”)	133,362,461.23	46,171,416.29
Of which: Gains from investment in associates and joint ventures	95,450,085.21	3,136,165.00
Gains from change in fair value (loss is represented by “()”)	(28,326,356.02)	12,557,529.72
Impairment loss of credit (loss is represented by “()”)	(12,769,332.65)	(33,310,392.48)
Impairment loss of assets (loss is represented by “()”)	(46,972,252.43)	(16,648,779.04)
Gain from assets disposal (loss is represented by “()”)	(4,400,980.53)	25,074.35
III. Operating profit (loss is represented by “()”)	936,368,271.45	914,440,800.53
Add: Non-operating income	15,413,649.67	210,813.13
Less: Non-operating expense	4,253,837.47	4,702,481.62

Item	Amount for the Period (January- September 2026)	Amount for the Previous period (January- September 2025)
IV. Total profit (total loss is represented by “()”)	947,528,083.65	909,949,132.04
Less: Income tax expense	104,395,913.29	117,470,631.06
V. Net profit (net loss is represented by “()”)	843,132,170.36	792,478,500.98
(I) Classified by continuity of operations		
1. Net profit from continuing operations (net loss is represented by “()”)	843,132,170.36	792,478,500.98
(II) Classified by ownership of equity		
1. Net profit attributable to the shareholders of the parent (net loss is represented by “()”)	852,184,750.57	800,245,215.12
2. Non-controlling interests (net loss is represented by “()”)	(9,052,580.21)	(7,766,714.14)
VI. Other comprehensive income, net of tax	(12,931,554.07)	(39,233.48)
Other comprehensive income attributable to the owners of the parent, net of tax	(12,931,554.07)	(39,233.48)
Other comprehensive income to be reclassified to profit or loss	(12,931,554.07)	(39,233.48)
Exchange differences on translation of foreign currency financial statements	(12,931,554.07)	(39,233.48)
VII. Total comprehensive income	830,200,616.29	792,439,267.50
(I) Total comprehensive income attributable to the owners of the parent company	839,253,196.50	800,205,981.64
(II) Total comprehensive income attributable to non-controlling shareholders	(9,052,580.21)	(7,766,714.14)
VIII. Earnings per share:		
(I) Basic earnings per share	2.36	2.18
(II) Diluted earnings per share	2.36	2.18

For the business consolidation under common control during the period, the net profit realised by the merged party before the combination was RMB0.00, and the net profit realised by the merged party in the previous period was RMB0.00.

Legal representative:
HAO HONG

Accounting chief:
Zhang Da

Person-in-charge of the
accounting department:
Huang Mo

3. Consolidated Statement of Cash Flows from the Beginning of the Year to the End of the Reporting Period

Unit: RMB

Item	Amount for the Period (January- September 2026)	Amount for the Previous period (January- September 2025)
I. Cash flow from operating activities:		
Received from the sales of goods and the rendering of services	5,555,391,329.51	5,037,168,978.30
Receipts of tax and surcharges refunds	132,285,930.47	255,321,328.87
Cash received relating to other operating activities	157,678,805.35	164,462,856.08
Sub-total of cash inflows from operating activities	5,845,356,065.33	5,456,953,163.25
Cash paid to the purchase of goods and services	2,332,897,838.14	1,727,987,732.12
Cash paid to and for employees	2,259,244,060.23	1,857,493,317.21
Payments of all types of taxes	251,153,789.93	292,634,977.35
Cash payments relating to other operating activities	396,744,082.58	434,678,511.89
Sub-total of cash outflows from operating activities	5,240,039,770.88	4,312,794,538.57
Net cash flow from operating activities	605,316,294.45	1,144,158,624.68
II. Cash flow from investing activities:		
Cash received from returns on investments	197,957,927.78	121,103,847.08
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	649,479.60	25,146.80
Cash received relating to other investing activities	13,747,875,542.20	8,808,496,506.81
Sub-total of cash inflows from investing activities	13,946,482,949.58	8,929,625,500.69

Item	Amount for the Period (January- September 2026)	Amount for the Previous period (January- September 2025)
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,408,553,554.16	838,008,321.52
Cash payments relating to other investing activities	12,974,355,829.60	8,205,047,033.02
Sub-total of cash outflows from investing activities	14,382,909,383.76	9,043,055,354.54
Net cash flow from investing activities	(436,426,434.18)	(113,429,853.85)
III. Cash flow from financing activities:		
Cash received from capital contribution	365,368,231.38	160,334,216.00
Cash received from borrowings	449,783,598.29	—
Sub-total of cash inflows from financing activities	815,151,829.67	160,334,216.00
Cash repayments of borrowings	49,783,598.29	—
Cash payments for distribution of dividends, profits, or interest expenses	465,575,431.44	395,179,359.23
Cash payments relating to other financing activities	378,211,280.32	85,962,276.36
Sub-total of cash outflows from financing activities	893,570,310.05	481,141,635.59
Net cash flow from financing activities	(78,418,480.38)	(320,807,419.59)
IV. Effect of foreign exchange rate changes on cash and cash equivalents	(194,696,500.77)	1,214,672.47
V. Net increase in cash and cash equivalents	(104,225,120.88)	711,136,023.71
Add: Balance of cash and cash equivalents at the beginning of the period	3,403,333,380.77	3,009,209,193.34
VI. Balance of cash and cash equivalents at the end of the period	3,299,108,259.89	3,720,345,217.05

4. *Non-IFRS Measures*

Item	For the nine months ended 30 September 2026 RMB'000 (except percentage)	For the nine months ended 30 September 2025 RMB'000 (except percentage)
Net profit attributable to shareholders of the listed company	852,185	800,245
Add:		
Amortization expenses of share-based compensation	54,720	46,287
Gain or loss on exchange rate fluctuations	238,455	50,168
Realised and unrealised losses on equity instrument investments	(71,748)	(15,325)
Adjusted net profit attributable to shareholders of the listed company	<u>1,073,612</u>	<u>881,375</u>
Adjusted net profit margin attributable to shareholders of the listed company	19.90%	19.04%

(II) Particulars in Relation to Adjustments Made to the Financial Statements as at the Beginning of the Year of the Initial Adoption of the New Accounting Standards since 2026

☐ Applicable ☒ Not Applicable

(III) Quarterly consolidated financial statements prepared in accordance with IFRSs

Consolidated Statement of Profit or Loss

January to September 2026

Unit: RMB'000

	January to September 2026	January to September 2025
Revenue	5,394,933	4,629,877
Cost of sales	<u>(3,153,373)</u>	<u>(2,674,538)</u>
Gross profit	2,241,560	1,955,339
Other income and gains	207,797	266,106
Selling and distribution expenses	(172,083)	(150,219)
Administrative expenses	(699,096)	(608,876)
Research and development expenses	(355,670)	(433,071)
Net impairment losses on financial and contract assets	(8,018)	(35,824)
Other expenses	(351,386)	(77,254)
Finance costs	(11,026)	(9,388)
Share of profit of associate	<u>95,450</u>	<u>3,136</u>
Profit before tax	947,528	909,949
Income tax expense	<u>(104,396)</u>	<u>(117,471)</u>
Profit for the period	<u>843,132</u>	<u>792,478</u>
Attributable to:		
Owners of the parent	852,185	800,245
Non-controlling interests	<u>(9,053)</u>	<u>(7,767)</u>
	<u>843,132</u>	<u>792,478</u>
Earnings per share attributable to ordinary equity holders of the parent		
Basic (expressed in RMB per share)	<u>2.36</u>	<u>2.18</u>
Diluted (expressed in RMB per share)	<u>2.36</u>	<u>2.18</u>

Consolidated Statements of Comprehensive Income
January to September 2026

Unit: RMB'000

	January to September 2026	January to September 2025
Profit for the period	843,132	792,478
Other comprehensive income		
Exchange differences on translation of foreign operations	(12,932)	(39)
Total comprehensive income for the period	830,200	792,439
Attributable to:		
Owners of the parent	839,253	800,206
Non-controlling interests	(9,053)	(7,767)
	830,200	792,439

Consolidated Statement of Financial Position
30 September 2026

Unit: RMB'000

	30 September 2026	31 December 2025
Non-current assets		
Property, plant and equipment	7,158,632	6,441,721
Right-of-use assets	713,299	669,608
Goodwill	146,183	146,183
Other intangible assets	22,471	25,000
Deferred tax assets	300,156	275,619
Investments in associates	626,020	573,469
Prepayments, other receivables and other assets	675,745	446,007
Financial assets at fair value through profit or loss	188,174	193,523
Total non-current assets	9,830,680	8,771,130
Current assets		
Inventories	2,429,941	1,470,882
Trade receivables	2,147,522	1,977,465
Contract assets	95,270	83,165
Prepayments, other receivables and other assets	475,806	523,270
Tax recoverable	9,971	13,999

	30 September 2026	31 December 2025
Financial assets at fair value through profit or loss	2,461,309	1,116,584
Amounts due from a related party	21	21
Cash and bank balances	4,183,370	6,320,950
Total current assets	11,803,210	11,506,336
Current liabilities		
Trade payables	726,937	584,388
Other payables and accruals	1,679,249	1,247,315
Financial liabilities at fair value through profit or loss	11,211	9,836
Interest-bearing bank borrowings	80,000	—
Lease liabilities	55,624	52,711
Tax payable	69,451	69,472
Amounts due to related parties	2,501	4,765
Total current liabilities	2,624,973	1,968,487
Net current assets	9,178,237	9,537,849
Total assets less current liabilities	19,008,917	18,308,979
Non-current liabilities		
Interest-bearing bank borrowings	320,000	—
Deferred income	326,436	294,734
Lease liabilities	233,798	256,473
Provision	28	28
Deferred tax liabilities	139,896	111,604
Other non-current liabilities	178,216	—
Total non-current liabilities	1,198,374	662,839
Net assets	17,810,543	17,646,140
Equity		
Equity attributable to owners of the parent		
Share capital	375,455	360,561
Treasury shares	(1,146,782)	(838,449)
Reserves	18,578,519	18,112,987
Non-controlling interests	3,351	11,041
Total equity	17,810,543	17,646,140

Consolidated Statement of Cash Flows
January to September 2026

Unit: RMB'000

	January to September 2026	January to September 2025
Cash flows from operating activities		
Profit before tax	947,528	909,949
Adjustments for:		
Finance costs	11,026	9,388
Share of profit of associates	(95,450)	(3,136)
Interest income	(98,935)	(47,273)
Investment income	(37,912)	(61,090)
Fair value gains on financial assets/liabilities at fair value through profit or loss	292,204	63,118
Loss on disposal of items of property, plant and equipment	7,458	270
Depreciation of property, plant and equipment	405,928	354,209
Depreciation of right-of-use assets	67,557	49,827
Amortization of other intangible assets	3,523	3,391
Impairment losses on trade receivables and contract assets, net	8,018	35,824
Loss on impairment of inventories	51,724	14,135
Equity-settled share option expense	44,183	54,999
	<u>1,606,852</u>	<u>1,383,611</u>
Increase in pledged deposits	(15,949)	(74,209)
Increase in inventories	(959,059)	(303,275)
(Increase)/decrease in trade receivables	(170,057)	301,558
(Increase)/decrease in contract assets	(12,105)	8,067
(Increase)/decrease in prepayments, deposits and other receivables	(182,274)	9,050
Increase in trade payables	140,285	129,302
Increase/(decrease) in other payables and accruals	448,777	(17,310)
Cash generated from operations	856,470	1,436,794
Tax paid	(251,154)	(292,635)
Net cash flows from operating activities	605,316	1,144,159
Cash flows from investing activities		
Interest received	197,958	121,103
Purchases of items of property, plant and equipment and other intangible assets	(1,408,554)	(838,008)
Proceeds from disposal of items of property, plant and equipment	649	25
Purchase of investments at fair value through profit or loss	(11,509,262)	(4,871,145)

	January to September 2026	January to September 2025
Proceeds from disposal of investments at fair value through profit or loss	10,715,527	5,618,428
Purchase of time deposits	(1,446,240)	(3,324,912)
Proceeds from maturity of time deposits	3,031,020	3,170,233
(Increase)/decrease in cash deposits	(17,524)	10,846
Net cash flows used in investing activities	(436,426)	(113,430)
Cash flows from financing activities		
Proceeds from issue of employee stock option program	186,880	160,334
Capital injections from non-controlling shareholders of subsidiaries	178,488	—
Dividends paid to shareholders	(465,226)	(395,179)
New bank borrowings	449,784	—
Repayment of bank loans	(49,784)	—
Share repurchase payment	(359,436)	(62,767)
Principal portion of lease payments	(18,775)	(23,195)
Interest paid	(349)	—
Net cash flows used in financing activities	(78,418)	(320,807)
Net increase in cash and cash equivalents	90,472	709,922
Cash and cash equivalents at the beginning of the year	3,403,333	3,009,209
Effect of foreign exchange rate changes, net	(194,697)	1,214
Cash and cash equivalents at the end of the period	3,299,108	3,720,345
Analysis of balances of cash and cash equivalents		
Cash and cash equivalents as stated in the statement of financial position	4,183,370	6,661,660
Less: Term deposits with original maturity of more than three months	(688,504)	(2,815,880)
Pledged for letters of credit and others	(195,758)	(125,435)
Cash and cash equivalents as stated in the statement of cash flows	3,299,108	3,720,345

(IV) Auditors' Report

Whether this third quarterly report is audited or not

☐ Yes ☒ No

This third quarterly report of the Company is unaudited.